Current status of cancer immunotherapy
To prove clinical benefits of cancer vaccine is currently difficult, except for one phase III trial has documented improved overall survival with the vaccine, Sipuleucel‑T, although induction of anti-tumor immune responses through cancer vaccine is theoretically promising and would be straightforwar...
Bewaard in:
| Hoofdauteur: | |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
GN Corporation Limited
2014-04-01
|
| Reeks: | Journal of Stem Cells and Regenerative Medicine |
| Onderwerpen: | |
| Online toegang: | http://www.pubstemcell.com/monthly/010010200003.htm |
| Tags: |
Geen labels, Wees de eerste die dit record labelt!
|